Logo American Journal of Case Reports

Call: 1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo American Journal of Case Reports Logo American Journal of Case Reports Logo American Journal of Case Reports

16 July 2024: Articles  USA

Rhabdomyolysis Risk: The Dangers of , an Over-the-Counter Supplement

Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Rare disease, Adverse events of drug therapy, Clinical situation which can not be reproduced for ethical reasons

Ross Huff12AEF*, Katarzyna Karpinska-Leydier12EF, Gautam Maddineni12EF, Dustin Begosh-Mayne12EF

DOI: 10.12659/AJCR.943492

Am J Case Rep 2024; 25:e943492

0 Comments

Abstract

0:00

BACKGROUND: Over-the-counter (OTC) supplement use is a very common practice within the United States. Supplements are not tightly regulated by the Food and Drug Administration. There are many case reports involving OTC supplement adverse effects and medication interactions, but there remains minimal clinical research regarding these subjects. Rhabdomyolysis is one interaction and adverse effect frequently documented in case reports among a variety of OTC supplements, although, to date, there is no documentation of rhabdomyolysis occurring from an interaction between the supplement Tribulus terrestris and atorvastatin.

CASE REPORT: A 71-year-old man presented to the Emergency Department in rhabdomyolysis with a mild transaminitis after taking the over-the-counter supplement Tribulus terrestris while on long-term atorvastatin. His rhabdomyolysis peaked at day 4 after cessation of the Tribulus and atorvastatin and aggressive fluid resuscitation with a normal saline bolus at admission followed by a D5 sodium bicarbonate drip later transitioned to a normal saline drip with subsequent down-trending of the creatinine phosphokinase levels.

CONCLUSIONS: Tribulus terrestris is an herbal supplement used for erectile dysfunction and energy. Recent research suggests it to be a moderate CYP 3A4 inhibitor that plays a significant role in metabolism of statin and many other commonly prescribed medications. This may put patients at increased risk of developing serious adverse effects, including rhabdomyolysis and drug-induced liver injury. Screening patients for over-the-counter supplement use and educating them on the potential risks of their use is extremely important for inpatient and outpatient healthcare professionals to avoid dangerous medication interactions.

Keywords: Cytochrome P-450 CYP3A, Dietary Supplements, Drug-Related Side Effects and Adverse Reactions, rhabdomyolysis, Transaminases, Tribulus

Introduction

Rhabdomyolysis is a breakdown (“lysis”) of the muscle cells in the body, leading to a variety of symptoms and complications, including myalgias, hyperkalemia, and acute kidney injury [1–3]. This pathological process has many causes, with trauma and drug-induced being the most common. Drug-induced rhabdomyolysis is well described, especially among the statin medication class [1–3]. Rhabdomyolysis contributed to by herbal supplementation, including but not limited to licorice, red yeast rice, and jimson weed, is less well described, but there are reports found in the literature [4,5]. An area where there remains a paucity of research involves drug interactions between the statin medication class and herbal supplements. We describe what we believe to be the first known case of a medication-supplement-induced interaction between atorvastatin and the herbal supplement Tribulus terrestris, resulting in rhabdomyolysis.

Case Report

A 71-year-old man with a past medical history of coronary artery disease and hyperlipidemia presented to the Emergency Department for chest pain onset that morning. He woke up in his usual state of health but developed worsening cramping muscular pains in his extremities, which progressed into his chest. He denied any recent trauma or illnesses. He had no history of renal dysfunction or thyroidal illness. He admitted to drinking 3–4 beers on the weekend but denied any history of recreational drug use. He cycles 15 miles once a week for exercise but had not since the prior week. Medications included baby aspirin 81 mg daily, metoprolol succinate 100 mg daily, and long-term atorvastatin 40 mg daily. He had recently begun taking the supplement Tribulus terrestris 500 mg capsules once daily as directed per the bottle 2 weeks prior for energy. Physical examination revealed diffuse muscle tenderness. Laboratory test results demonstrated a creatine phosphokinase (CPK) of 7555 U/L, aspartate aminotransferase (AST) 152 U/L, alanine aminotransferase (ALT) 74 U/L, alkaline phosphatase (ALP) 74 U/L, total bilirubin 0.9 mg/dL, creatinine 0.83 mg/dL, and urinalysis with large amounts of blood and no red blood cells, consistent with rhabdomyolysis. His statin medication was held, and aggressive intravenous hydration was initiated with a 1-L bolus of normal saline at admission, followed by 150 meq sodium bicarbonate in D5 at 200 mL/hr for 24 h, then transitioned to normal saline at 75 mL/h until discharge. His CPK peaked on day 4 at 11 972 U/L before rapidly down-trending to 6610U/L the following 2 days (Figure 1). His AST also peaked at day 4 at 542 U/L (Figure 2). His ALT continued to show a slow increase up to his day of discharge at a level of 266 U/L (Figure 2). ALP and bilirubin never elevated above normal limits. Thankfully, during his admission he showed no evidence of renal dysfunction, as he had no elevation in creatinine past baseline or a decrease in urine output. He was discharged after a noted down-trend of the CPK and resolution of his symptoms. He was instructed to discontinue the use of atorvastatin and Tribulus terrestris and follow-up with his primary care physician for continued monitoring.

Discussion

While statin-induced myopathy is a commonly known adverse effect, with rhabdomyolysis being the most severe form, there is a low risk of it occurring. Clinical studies show the risk of serious muscle injury from statin use is <0.1%, with the highest risk occurring within the first year of treatment, increasing the dosage, or addition of an interacting drug [6]. Our patient had been on high-intensity atorvastatin for 6 years without complication until recent initiation of the herbal supplement Tribulus terrestris. Tribulus terrestris is sold commercially for erectile dysfunction and increased energy from its presumed testosterone-boosting effects. However, clinical trials continue to show varying results, with disagreements about the actual benefits the supplement provides. Often, the compounds tested vary significantly in their composition and biological properties as there is no standardization of its formulation. It is also marketed as being safe with minimal to no adverse effects, but information supporting this is lacking [7]. Recent research shows Tribulus terrestris to be a moderate inhibitor of cytochrome P450 3A4 (CYP 3A4), a significant factor in statin metabolism [8]. We hypothesize that the addition of Tribulus terrestris resulted in a medication interaction with atorvastatin, leading to an acute rise in serum levels, inducing rhabdomyolysis. Additionally, a case report of rhabdomyolysis contributed to by Tribulus terrestris use and clinical research demonstrating liver failure and muscle injury in sheep grazing on the natural plant suggests Tribulus terrestris drives its own process in causing rhabdomyolysis [9,10]. There are also 2 documented reports of severe nephrotoxicity from acute tubular necrosis contributed to by use of Tribulus terrestris in young male patients who had no prior renal disease [11,12]. The unregulated use of this supplement is concerning as it is known the cytochrome p450 metabolic pathway is foremost in a vast array of prescription medications, many of which can have adverse effects if serum levels rise unchecked. Further research regarding Tribulus terrestris’ adverse effects profile and its CYP inhibition is needed.

Conclusions

Herbal supplementation is a common practice with minimal regulation or safety profile research, which opens the door for dangerous adverse effects and medication interactions among unsuspecting patients. Patients often do not readily mention over-the-counter supplements when asked about their home medications, so it is the physician’s responsibility to actively screen patients regarding supplement use, both inpatient and outpatient, and provide the necessary education to prevent harm. Physicians and other healthcare professionals need to be aware of the commonly used and emerging supplements such as Tribulus terrestris to warn their patients and be prepared to prevent and manage complications of their use when they occur.

References:

1.. Cabral BMI, Edding SN, Portocarrero JP, Lerma EV, Rhabdomyolysis: Dis Mon, 2020; 66(8); 101015

2.. Hohenegger M, Drug induced rhabdomyolysis: Curr Opin Pharmacol, 2012; 12(3); 335-39

3.. Sharma U, Statin-induced delayed rhabdomyolysis: BMJ Case Rep, 2019; 12(9); e231125-31 [Corrected in: Drug Ther Bull. 2020;58(2):

4.. Navarro VJ, Herbal and dietary supplement hepatotoxicity: Semin Liver Dis, 2009; 29(4); 373-82

5.. Allkanjari O, Menniti-Ippolito F, Ippoliti I, A descriptive study of commercial herbal dietary supplements used for dyslipidemia-Sales data and suspected adverse reactions: Phytother Res, 2022; 36(6); 2583-604

6.. Newman CB, Preiss D, Tobert JA, Statin safety and associated adverse events: A scientific statement from the American Heart Association: Arterioscler Thromb Vasc Biol, 2019; 39(2); e38-e81

7.. Ștefănescu R, Tero-Vescan A, Negroiu A: Biomolecules, 2020; 10(5); 752

8.. Wang B, Shi C, Feng L: Front Pharmacol, 2022; 13; 856784

9.. Chen A, Lim B, Chaya C: Am J Gastroenterol, 2013; 108; S353

10.. Aslani MR, Movassaghi AR, Mohri M: Vet Res Commun, 2003; 27(1); 53-62

11.. Ryan M, Lazar I, Nadasdy GM: Clin Nephrol, 2015; 83(3); 177-83

12.. Talasaz A: Nephrol Dial Transplant, 2010; 25(11); 3792-93

In Press

Case report  USA

Acute Heart Failure and Complete Heart Block in a Patient with Recurrent Diffuse Large B-Cell Lymphoma: A C...

Am J Case Rep In Press; DOI: 10.12659/AJCR.945085  

Case report  Indonesia

Successful Triple Flap Procedure for Thumb Reconstruction in Severe Hand Crush Injury

Am J Case Rep In Press; DOI: 10.12659/AJCR.945759  

Case report  USA

Improving Golf Swing Kinematics in a 78-Year-Old Golfer with Lower Back Pain: A Case Report

Am J Case Rep In Press; DOI: 10.12659/AJCR.946077  

Case report  France

Successful Aflibercept Treatment for Choroidal Neovascularization in a Rare Case of Optic Disc Melanocytoma

Am J Case Rep In Press; DOI: 10.12659/AJCR.944211  

Most Viewed Current Articles

21 Jun 2024 : Case report  China (mainland) 77,727

Intracranial Parasitic Fetus in a Living Infant: A Case Study with Surgical Intervention and Prognosis Anal...

DOI :10.12659/AJCR.944371

Am J Case Rep 2024; 25:e944371

0:00

07 Mar 2024 : Case report  USA 45,935

Neurocysticercosis Presenting as Migraine in the United States

DOI :10.12659/AJCR.943133

Am J Case Rep 2024; 25:e943133

0:00

10 Jan 2022 : Case report  Germany 32,872

A Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV...

DOI :10.12659/AJCR.935263

Am J Case Rep 2022; 23:e935263

23 Feb 2022 : Case report  USA 21,280

Penile Necrosis Associated with Local Intravenous Injection of Cocaine

DOI :10.12659/AJCR.935250

Am J Case Rep 2022; 23:e935250

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

American Journal of Case Reports eISSN: 1941-5923
American Journal of Case Reports eISSN: 1941-5923